Clinical Trials
9 trialsNCT00096005 2014-02-24
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00104897 2013-06-26
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004065 2013-06-24
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00103272 2013-06-04
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00354185 2013-05-16
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00087386 2013-04-10
Tanespimycin in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00004241 2013-02-07
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00627419 2012-12-10
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00004075 2011-08-03
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed